ATE213407T1 - Neue behandlungsmethoden durch verwendung von phenethylderivaten - Google Patents

Neue behandlungsmethoden durch verwendung von phenethylderivaten

Info

Publication number
ATE213407T1
ATE213407T1 AT94304252T AT94304252T ATE213407T1 AT E213407 T1 ATE213407 T1 AT E213407T1 AT 94304252 T AT94304252 T AT 94304252T AT 94304252 T AT94304252 T AT 94304252T AT E213407 T1 ATE213407 T1 AT E213407T1
Authority
AT
Austria
Prior art keywords
alkyl
hydrogen
disorder
syndrome
compound
Prior art date
Application number
AT94304252T
Other languages
English (en)
Inventor
Richard Leslie Rudolph
Albert Thomas Derivan
Eric Anthony Muth
Gertrude Virginia Upton
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22181084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE213407(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of ATE213407T1 publication Critical patent/ATE213407T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT94304252T 1993-06-28 1994-06-13 Neue behandlungsmethoden durch verwendung von phenethylderivaten ATE213407T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8384893A 1993-06-28 1993-06-28

Publications (1)

Publication Number Publication Date
ATE213407T1 true ATE213407T1 (de) 2002-03-15

Family

ID=22181084

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06017469T ATE392893T1 (de) 1993-06-28 1994-06-13 Neue behandlungsmethoden durch verwendung von phenethylaminderivaten
AT94304252T ATE213407T1 (de) 1993-06-28 1994-06-13 Neue behandlungsmethoden durch verwendung von phenethylderivaten
AT01115854T ATE342715T1 (de) 1993-06-28 1994-06-13 Neue behandlungsmethoden durch verwendung von phenethylderivaten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06017469T ATE392893T1 (de) 1993-06-28 1994-06-13 Neue behandlungsmethoden durch verwendung von phenethylaminderivaten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01115854T ATE342715T1 (de) 1993-06-28 1994-06-13 Neue behandlungsmethoden durch verwendung von phenethylderivaten

Country Status (16)

Country Link
US (8) US5916923A (de)
EP (3) EP0639374B1 (de)
JP (2) JPH0789851A (de)
KR (1) KR100342762B1 (de)
AT (3) ATE392893T1 (de)
AU (2) AU6592994A (de)
CA (1) CA2126305C (de)
CY (1) CY2315B1 (de)
DE (3) DE69434872T2 (de)
DK (3) DK1153603T3 (de)
ES (3) ES2273764T3 (de)
HK (1) HK1038880B (de)
LV (1) LV12881B (de)
PT (3) PT1738753E (de)
PY (1) PY0101636A (de)
SG (1) SG47711A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
EP0667150B1 (de) * 1994-02-14 2002-12-11 Wyeth Venlafaxin und seine Analoga zum Herbeiführen einer Verbesserung der kognitiven Funktionen
EP1331003B1 (de) * 1996-03-25 2015-08-26 Wyeth LLC Venlafaxinhaltige Arzneizusammensetzung mit verzögerter Wirkstoffabgabe
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
EP1096927A4 (de) * 1998-07-16 2002-09-04 Massachusetts Inst Technology Zusammensetzung für stressbehandlung
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
HUP0200898A3 (en) 1999-04-06 2005-09-28 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US7291646B2 (en) 1999-11-24 2007-11-06 Wyeth Ethers of O-desmethyl venlafaxine
EP1246817B1 (de) * 1999-12-30 2004-06-23 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl und -tetrahydropyridyl-derivate
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
FR2807753B1 (fr) * 2000-04-13 2002-06-07 Adir Nouveaux derives d'heterocycloalkylbenzocyclobutane et d'heteroarylbenzocyclobutane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2319826A1 (de) * 2001-02-12 2011-05-11 Wyeth LLC O-Desmethyl-Venlafaxine Succinat Salz
KR100421508B1 (ko) * 2001-08-07 2004-03-09 김정한 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염
AU2002348266A1 (en) * 2001-12-05 2003-06-23 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
US20030191347A1 (en) * 2002-03-28 2003-10-09 Rolf Keltjens Venlafaxine base
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
WO2003082805A1 (en) 2002-03-28 2003-10-09 Synthon B.V. Low water-soluble venlafaxine salts
US6717015B2 (en) 2002-03-28 2004-04-06 Synthon Bv Venlafaxine besylate
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
AU2003278549A1 (en) * 2002-11-28 2004-06-18 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
WO2004075902A1 (en) * 2003-02-28 2004-09-10 Amedis Pharmaceuticals Ltd. Use of silicon derivatives of venlafaxine for the treatment or prevention of psoriasis or panic disorder
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
US20050226923A1 (en) * 2004-04-07 2005-10-13 Gassert Chad M Venlafaxine compositions in the form of microtablets
RU2281788C2 (ru) * 2004-04-19 2006-08-20 Николай Иванович Косенков Способ ультрапарадоксальной психотерапии в лечении психосоматических заболеваний и измененных функциональных состояний человека
RU2276999C2 (ru) * 2004-05-06 2006-05-27 Анатолий Викторович Осницкий Метод коррекции психических состояний и лечения невротических расстройств и патологических зависимостей "интегрально-синергетическая психотерапия"
RU2270036C1 (ru) * 2004-07-14 2006-02-20 Государственное учреждение "Нижегородский научно-исследовательский институт травматологии и ортопедии Министерства здравоохранения Российской Федерации" Способ коррекции психоэмоциональных и психосоматических расстройств у детей с термической травмой
US7776358B2 (en) * 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
RU2273498C1 (ru) * 2004-08-04 2006-04-10 Анатолий Анатолиевич Чумаченко Способ "табу" лечения зависимых форм поведения
RU2272657C1 (ru) * 2005-01-19 2006-03-27 Ирина Анатольевна Нелаева Способ информационно-трансового кодирования в лечении алкоголизма
US20060193912A1 (en) * 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co. Controlled release O-desmethylvenlafaxine formulations
AU2006239920A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
CA2604915A1 (en) * 2005-04-22 2006-11-02 Wyeth New therapeutic combinations for the treatment or prevention of depression
JP2008538573A (ja) * 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその５−ｈｔ２ｃアゴニストとしての使用
AU2006239897A1 (en) * 2005-04-22 2006-11-02 Wyeth Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
CA2625832A1 (en) * 2005-10-19 2007-04-26 Vinod Kumar Kansal Process for the preparation of highly pure 1-[2-dimethylamino-(4-methoxyphenyl) ethyl]cyclohexanol hydrochloride
PT1954669E (pt) * 2005-12-01 2015-10-23 Auspex Pharmaceuticals Inc Feniletilaminas substituídas com actividade serotoninérgica e/ou norepinefrinérgica
JP2009518407A (ja) 2005-12-05 2009-05-07 ワイス 置換１−（２−アミノ−１−フェニル−エチル）−シクロヘキサノールのエナンチオマーを選択的に合成するための方法
CN101410112A (zh) * 2006-03-24 2009-04-15 惠氏公司 治疗抑郁症的新治疗组合
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
RU2009112105A (ru) * 2006-10-25 2010-11-27 Вайет (Us) Выделенные гидрокси- и n-оксидные метаболиты и производные о-дезметилвенлафаксина и способы лечения
ES2693948T3 (es) * 2007-03-15 2018-12-14 Auspex Pharmaceuticals, Inc. Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
WO2009023820A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
WO2009065845A1 (en) * 2007-11-20 2009-05-28 Neurosearch A/S A method for treating over-eating disorders
KR100965527B1 (ko) 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
CZ301820B6 (cs) * 2009-02-06 2010-06-30 Zentiva, K.S. Nové soli desvenlafaxinu a zpusob jejich prípravy
US20140116656A1 (en) * 2012-10-25 2014-05-01 Inhon International Co., Ltd Heat dissipation module and electronic device with the same
KR102132304B1 (ko) 2020-02-17 2020-07-09 박광순 접이식 유아용 비데
RU2741226C1 (ru) * 2020-09-08 2021-01-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ профилактики агрессии лиц с интернет-зависимостью

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017637A (en) * 1973-03-26 1977-04-12 American Home Products Corporation Benzylamine analgesics
US3894051A (en) * 1973-07-05 1975-07-08 Colgate Palmolive Co N-methylenedioxyphenylalkyl)-{62 -(alkyl)-disubstituted phenethylamines
US4435449A (en) * 1981-05-14 1984-03-06 Burroughs Wellcome Co. Treatment of minimal brain dysfunction (MBD)
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
AU566673B2 (en) * 1983-09-15 1987-10-29 F. Hoffmann-La Roche Ag Phenethylamine derivatives
US4611078A (en) * 1983-10-26 1986-09-09 American Home Products Corporation Substituted phenylacetonitriles
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4609758A (en) * 1985-05-09 1986-09-02 American Home Products Corporation Phenoxyethylamine derivatives
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
ATE175358T1 (de) * 1987-10-22 1999-01-15 Massachusetts Inst Technology Behandlung des prämenstruellen oder späten lutealsphase-syndroms
US4996235A (en) * 1987-11-25 1991-02-26 Eli Lilly And Company 3,4-diphenylbutanamines
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5006525A (en) * 1989-07-24 1991-04-09 Eli Lilly And Company Dopamine agonists method
US5057515A (en) * 1989-07-24 1991-10-15 Eli Lilly And Company Method for agonizing a dopamine receptor
FI910897L (fi) * 1990-02-28 1991-08-29 Lilly Co Eli Foerbaettringar roerande (s)-norfluoxetin.
EP0449562A3 (en) * 1990-03-29 1992-03-18 Eli Lilly And Company Use of r-fluoxetine as selective serotonin ic-receptor ligands
WO1993009769A1 (en) * 1991-11-15 1993-05-27 Sepracor, Inc. Methods and compositions utilizing pure s(+) isomer fluoxetine
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
TW460478B (en) * 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives

Also Published As

Publication number Publication date
DE69434872T2 (de) 2007-04-05
KR950000139A (ko) 1995-01-03
EP1738753A2 (de) 2007-01-03
KR100342762B1 (ko) 2002-11-18
EP0639374A3 (de) 1995-08-02
EP0639374B1 (de) 2002-02-20
EP1153603A3 (de) 2003-05-21
US5916923A (en) 1999-06-29
US6310101B1 (en) 2001-10-30
US6444708B2 (en) 2002-09-03
CA2126305A1 (en) 1994-12-29
AU5831298A (en) 1998-05-21
EP1153603B1 (de) 2006-10-18
JPH0789851A (ja) 1995-04-04
US20010012855A1 (en) 2001-08-09
US6555586B2 (en) 2003-04-29
DK0639374T3 (da) 2002-05-06
PT1738753E (pt) 2008-06-19
DK1738753T3 (da) 2008-08-11
US20080176950A1 (en) 2008-07-24
US6730706B2 (en) 2004-05-04
ATE392893T1 (de) 2008-05-15
ATE342715T1 (de) 2006-11-15
LV12881B (en) 2002-11-20
CY2315B1 (en) 2003-11-14
ES2304041T3 (es) 2008-09-01
AU6592994A (en) 1995-01-05
EP1153603A2 (de) 2001-11-14
US6465524B2 (en) 2002-10-15
DE69434872D1 (de) 2006-11-30
US20030181517A1 (en) 2003-09-25
ES2174864T3 (es) 2002-11-16
DE69429895D1 (de) 2002-03-28
ES2273764T3 (es) 2007-05-16
EP1738753B1 (de) 2008-04-23
HK1038880A1 (en) 2002-04-04
JP2006117689A (ja) 2006-05-11
EP0639374A2 (de) 1995-02-22
EP1738753A3 (de) 2007-01-31
DE69435095D1 (de) 2008-06-05
US20010053799A1 (en) 2001-12-20
CA2126305C (en) 2006-10-17
DK1153603T3 (da) 2006-12-18
DE69435095T2 (de) 2009-07-02
HK1038880B (en) 2006-12-22
PY0101636A (es) 2001-12-03
US20040110829A1 (en) 2004-06-10
DE69429895T2 (de) 2002-08-29
PT1153603E (pt) 2007-01-31
SG47711A1 (en) 1998-04-17
US20020052405A1 (en) 2002-05-02
PT639374E (pt) 2002-07-31

Similar Documents

Publication Publication Date Title
DE69429895D1 (de) Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten
NO942415L (no) Fremgangsmåte for fremstilling av behandling av surgass og hydrokarbonvæskeströmmer
DK0582790T3 (da) Ny fremgangsmåde til fremstilling af 7-substituerede-9-[(substitueret glycyl)-amino]-6-demethyl-6-deoxytetracycliner
DE69133455D1 (de) Zwischenprodukte zur Herstellung von Camptothecin und Analogen
DE69628466D1 (de) Zwischenverbindungen zur Herstellung von neunen Pyridoncarbonsäurederivate oder deren Salzen
RU99111492A (ru) N-замещенные 2-цианопирролидины
AR001074A1 (es) Composición para tratar amenorrea hipotalamica en un mamifero hembra no deprimido
SG165991A1 (en) Methods of treating gastrointestinal and genitourinary pain disorders using vinlafaxin and derivatives
HU9601217D0 (en) Antracyclinone derivatives and their use for treating amyloidosis
AU2186288A (en) Novel amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same
NO870423D0 (no) 5-substituert octahydroindolizin-analgetika-forbindelser og 7-keto-mellomprodukt.
FI860074A0 (fi) Oktahydroindolizinfoereningar anvaendbara som smaertstillande medel.
DK0667150T3 (da) Venlafaxin og dens analoger til fremkaldelse af en forbedring af de kognitive funktioner
AU6741690A (en) 4-heteroaryl piperidine intermediates and their preparation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification